Amgen's Q3 Earnings Soar on Strong Product Sales, R&D Spikes

Ticker: AMGN · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: bullish

Topics: Biotechnology, Pharmaceuticals, Earnings, R&D Spending, Product Sales, Net Income Growth, 10-Q Filing

Related Tickers: AMGN, AZN, BGNE, NEMO

TL;DR

**Amgen's Q3 numbers are a clear buy signal, with revenue and net income surging, proving their R&D investments are paying off despite increased impairment charges.**

AI Summary

Amgen Inc. reported robust financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 12.4% to $9.557 billion for the three months ended September 30, 2025, up from $8.503 billion in the same period of 2024. Product sales were the primary driver, growing from $8.151 billion to $9.137 billion, a 12.1% increase. Net income saw a significant jump, rising 13.6% to $3.216 billion for the three-month period, compared to $2.830 billion in 2024. Diluted EPS also increased from $5.22 to $5.93. For the nine months ended September 30, 2025, total revenues reached $26.885 billion, a 10.5% increase from $24.338 billion in 2024, while net income surged by 84.2% to $6.378 billion from $3.463 billion. Research and development expenses increased by 31% to $1.900 billion for the three-month period, reflecting continued investment in its pipeline. The company also noted an impairment of intangible assets totaling $1.200 billion for the nine months ended September 30, 2025, significantly higher than $129 million in the prior year.

Why It Matters

Amgen's strong revenue and net income growth signal healthy demand for its human therapeutics, which is positive for investors looking for stable pharmaceutical sector returns. The substantial increase in R&D spending, up 31% to $1.900 billion, indicates aggressive pipeline development, potentially leading to future blockbuster drugs and competitive advantages against rivals like AstraZeneca and BeiGene. For employees, this growth could mean job security and opportunities in research and development. Customers may benefit from new innovative treatments emerging from Amgen's expanded R&D efforts, while the broader market sees a major biotech player reinforcing its leadership position, potentially influencing sector-wide innovation and pricing strategies.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant increase in 'Impairment of intangible assets' to $1.200 billion for the nine months ended September 30, 2025, compared to $129 million in the prior year, which could indicate challenges with certain acquired assets or pipeline projects. Additionally, the 'Other operating expenses' category jumped from $71 million to $329 million for the three months ended September 30, 2025, suggesting potential unforeseen costs or operational hurdles.

Analyst Insight

Investors should consider Amgen's strong revenue and net income growth as a positive indicator for long-term holding. While the increased impairment of intangible assets warrants monitoring, the substantial R&D investment suggests a commitment to future growth. Investors should evaluate the specific drivers of the 'Other operating expenses' increase for clarity.

Financial Highlights

debt To Equity
1.56
revenue
$9.557B
operating Margin
26.4%
total Assets
$90.141B
total Debt
$54.587B
net Income
$3.216B
eps
$5.93
gross Margin
67.2%
cash Position
$9.445B
revenue Growth
+12.4%

Revenue Breakdown

SegmentRevenueGrowth
Product sales$9,137M+12.1%
Other revenues$420M+19.3%

Key Numbers

Key Players & Entities

FAQ

What were Amgen's total revenues for the third quarter of 2025?

Amgen's total revenues for the three months ended September 30, 2025, were $9.557 billion, an increase from $8.503 billion in the same period of 2024.

How did Amgen's net income change in Q3 2025 compared to Q3 2024?

Amgen's net income increased by 13.6% to $3.216 billion for the three months ended September 30, 2025, up from $2.830 billion in the third quarter of 2024.

What was Amgen's research and development expense for Q3 2025?

Amgen's research and development expenses for the three months ended September 30, 2025, were $1.900 billion, a 31% increase from $1.450 billion in the prior year's third quarter.

What was the impact of intangible asset impairment on Amgen's financials?

For the nine months ended September 30, 2025, Amgen reported an impairment of intangible assets totaling $1.200 billion, a significant increase from $129 million in the same period of 2024.

How much cash and cash equivalents did Amgen have as of September 30, 2025?

As of September 30, 2025, Amgen had $9.445 billion in cash and cash equivalents, a decrease from $11.973 billion at December 31, 2024.

What is Amgen's primary business segment?

Amgen operates its business in one operating segment, human therapeutics, which focuses on the discovery, development, manufacturing, and delivery of innovative human therapeutics.

What new accounting standards might affect Amgen in the future?

Amgen is evaluating new FASB ASUs, including ASU No. 2023-09 (Income Tax Disclosures, effective after Dec 15, 2024), ASU No. 2024-03 (Expense Disaggregation, effective after Dec 15, 2026), and ASU No. 2025-06 (Internal-Use Software, effective after Dec 15, 2027).

How many shares of common stock did Amgen have outstanding as of October 30, 2025?

As of October 30, 2025, Amgen had 538,480,671 shares of common stock, $0.0001 par value, outstanding.

What was Amgen's diluted EPS for the nine months ended September 30, 2025?

Amgen's diluted EPS for the nine months ended September 30, 2025, was $11.77, a substantial increase from $6.40 in the same period of 2024.

Did Amgen's long-term debt change significantly?

Yes, Amgen's long-term debt decreased to $52.434 billion as of September 30, 2025, from $56.549 billion at December 31, 2024.

Risk Factors

Industry Context

Amgen operates in the highly competitive global biotechnology sector, focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. The industry is characterized by significant R&D investment, long product development cycles, and reliance on scientific innovation. Key trends include advancements in biologics, gene therapy, and personalized medicine, alongside increasing pricing pressures and regulatory scrutiny.

Regulatory Implications

Amgen faces significant regulatory hurdles in obtaining and maintaining approvals for its products across various global markets. Changes in regulatory frameworks, such as those related to drug pricing or manufacturing standards, could impact the company's operations and profitability. Compliance with stringent FDA and international regulations is paramount.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Intangible assets, net
Assets that lack physical substance but are identifiable and controlled by the company, such as patents, trademarks, and goodwill. 'Net' indicates accumulated amortization. (A significant impairment of $1.200 billion was recorded in YTD 2025, impacting profitability and asset valuation.)
Diluted EPS
Earnings per share calculated by dividing net income by the weighted-average number of diluted common shares outstanding. It accounts for all potential dilutive common shares. (Increased to $5.93 in Q3 2025 from $5.22 in Q3 2024, reflecting improved profitability on a per-share basis.)
Operating income
Profitability from a company's core business operations, calculated as total revenues minus cost of sales, R&D, SG&A, and other operating expenses. (Increased to $2.526 billion in Q3 2025 from $2.047 billion in Q3 2024, showing improved operational efficiency.)
Comprehensive income
The total change in equity during a period from non-owner sources. It includes net income plus other comprehensive income (OCI) items like foreign currency translation adjustments. (Total comprehensive income increased to $3.338 billion in Q3 2025 from $2.649 billion in Q3 2024, driven by higher net income.)
Goodwill
An intangible asset that arises when one company acquires another for a price exceeding the fair market value of its identifiable net assets. It represents the future economic benefits arising from assets acquired in a business combination. (Remained stable at $18.676 billion, indicating no significant acquisitions or impairments related to goodwill in the period.)

Year-Over-Year Comparison

Compared to the prior year's nine months, Amgen has demonstrated strong top-line growth with total revenues increasing by 10.5% to $26.885 billion. Net income saw a dramatic surge of 84.2% to $6.378 billion, partly due to a significant decrease in interest expense and a substantial increase in other income, net. However, a major concern is the sharp rise in R&D expenses by 31% and a significant impairment of intangible assets ($1.200 billion vs. $129 million), which warrants close attention for future profitability and asset valuation.

Filing Stats: 4,599 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2025-11-04 18:59:36

Key Financial Figures

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 1

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS 1 CONDENSED CONSOLIDATED STATEMENTS OF INCOME 1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 2 CONDENSED CONSOLIDATED BALANCE SHEETS 3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 4 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 6 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 30

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 45

CONTROLS AND PROCEDURES

Item 4. CONTROLS AND PROCEDURES 45

—OTHER INFORMATION

PART II—OTHER INFORMATION 46

LEGAL PROCEEDINGS

Item 1. LEGAL PROCEEDINGS 46

RISK FACTORS

Item 1A. RISK FACTORS 46

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 53

OTHER INFORMATION

Item 5. OTHER INFORMATION 53

EXHIBITS

Item 6. EXHIBITS 53 INDEX TO EXHIBITS 54

SIGNATURES

SIGNATURES 61 i Defined Terms and Products Defined terms We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as well as names of other companies, which are provided below. Term Description 2017 Tax Act Tax Cuts and Jobs Act of 2017 340B Program Federal 340B Drug Pricing Program AOCI accumulated other comprehensive income (loss) AstraZeneca AstraZeneca plc BeOne BeOne Medicines Ltd. (formerly BeiGene, Ltd.) CMS Centers for Medicare & Medicaid Services EO Executive Order EPS earnings per share EU European Union FDA U.S. Food and Drug Administration Fitch Fitch Ratings, Inc. G7 Group of Seven (Canada, France, Germany, Italy, Japan, the United Kingdom and the United States) GAAP U.S. generally accepted accounting principles HHS U.S. Department of Health and Human Services Horizon Horizon Therapeutics plc IPR&D in-process research and development IRA Inflation Reduction Act of 2022 IRS Internal Revenue Service July MFN Letter Letter dated July 31, 2025, by the Administration to certain pharmaceutical manufacturers, including Amgen July Tariff EOs Executive orders issued by the Administration in July 2025 that raised or modified country-specific tariffs for more than 60 countries, effective August 7, 2025 Later-Stage Clinical Programs R&D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU Marketed Product Support R&D expenses incurred in support of the Company's marketed products that are authorized to be sold primarily in the United States or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regul

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

FINANCIAL STATEMENTS

Item 1. FINANCIAL STATEMENTS AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In millions, except per-share data) (Unaudited) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Revenues: Product sales $ 9,137 $ 8,151 $ 25,781 $ 23,310 Other revenues 420 352 1,104 1,028 Total revenues 9,557 8,503 26,885 24,338 Operating expenses: Cost of sales 3,082 3,310 9,061 9,746 Research and development 1,900 1,450 5,130 4,240 Selling, general and administrative 1,720 1,625 5,098 5,218 Other 329 71 1,236 187 Total operating expenses 7,031 6,456 20,525 19,391 Operating income 2,526 2,047 6,360 4,947 Other income (expense): Interest expense, net ( 685 ) ( 776 ) ( 2,102 ) ( 2,408 ) Other income, net 2,080 1,830 3,204 1,288 Income before income taxes 3,921 3,101 7,462 3,827 Provision for income taxes 705 271 1,084 364 Net income $ 3,216 $ 2,830 $ 6,378 $ 3,463 Earnings per share: Basic $ 5.98 $ 5.27 $ 11.86 $ 6.45 Diluted $ 5.93 $ 5.22 $ 11.77 $ 6.40 Weighted-average shares used in calculation of earnings per share: Basic 538 537 538 537 Diluted 542 542 542 541 See accompanying notes. 1 AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In millions) (Unaudited) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Net income $ 3,216 $ 2,830 $ 6,378 $ 3,463 Other comprehensive income (loss), net of reclassification adjustments and taxes: Gains on foreign currency translation adjustments 11 71 154 32 Gains (losses) on cash flow hedges 110 ( 253 ) ( 512 ) ( 76 ) Other 1 1 2 ( 3 ) Other comprehensive income (loss), net of reclassification adjustments and taxes 122 ( 181 ) ( 356 ) ( 47 ) Comprehensive income $ 3,338 $ 2,649 $ 6,022 $ 3,416 See accompanying notes. 2 AMGEN INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except per-share data) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash an

Business

Business Amgen Inc. (including its consolidated subsidiaries, referred to as "Amgen," "the Company," "we," "our" or "us") is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate our business in one operating segment: human therapeutics. See Note 2, Segment and other information. Basis of presentation The interim unaudited financial information for the three and nine months ended September 30, 2025 and 2024, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2024, and with the condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen and its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity's economic performance and the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolida

View on Read The Filing